

Please type a plus (+) inside this box →

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

J1131
01/22/02
U.S. PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 10412-022 Total Pages 84
First Named Inventor or Application Identifier
Robert E. KLEM
Express Mail Label No. EL 477 034 015 US

A
Box 5745
PTO/SB/02
01/22/02

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form
Submit an original, and a duplicate for fee processing
2. Applicant claims Small Entity status, see 37 C.F.R. § 1.27
3. Specification [Total Pages 68]
 - (preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (*if filed*)
 - Detailed Description of the Invention (including drawings, *if filed*)
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 USC 113) [Total Sheets]
5. Oath or Declaration [Total Sheets 2]
 - a. Unexecuted (original or copy)
 - b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 19 completed)
 - i. **DELETION OF INVENTORS(S)**


Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
6. Application Data Sheet. See 37 CFR 1.76
18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:
 Continuation Divisional Continuation-in-part (CIP) of prior application No: filed .

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. Computer Readable Copy
 - b. Paper Copy (identical to computer copy)
 - c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement *(when there is an assignee)* Power of Attorney
11. English Translation Document (*if applicable*)
12. Information Disclosure Statement Copies of IDS (IDS)/PTO-1449 Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(i).
Applicant must attach form PTO/SB/35 or its equivalent
17. Other:

Customer Number: 20583

(Insert Customer No. or Attach bar code label here)

or Correspondence address below

NAME					
ADDRESS					
CITY		STATE		ZIP CODE	
COUNTRY		TELEPHONE		FAX	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PENNIE & EDMONDS LLP
 COUNSELLORS AT LAW
 1155 Avenue of Americas
 New York, N.Y. 10036-2711

ATTORNEY DOCKET NO. 10412-022Date: January 22, 2002

Assistant Commissioner for Patents
 Box PATENT APPLICATION
 Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): Robert E. KLEM

Executed on: Unexecuted

Title of Invention: METHODS AND COMPOSITIONS FOR TREATING A CELL-PROLIFERATIVE DISORDER
 USING CRE DECOY OLIGOMERS, BCL-2 ANTISENSE OLIGOMERS, AND HYBRID
 OLIGOMERS THEREOF

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	Fee
Total Claims	71	-20	51	\$18.00 each	\$ 918.00
Independent	6	-3	3	\$84.00 each	\$ 252.00
				Minimum Fee	\$ 740.00
				Multiple Dependency Fee If Applicable (\$280.00)	\$ 0.00
				Total	\$ 1,910.00
					- \$ 955.00
				Total Filing Fee	\$ 955.00

- DO NOT PUBLISH.** I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
- Priority of application no. 60/283,244 filed on January 22, 2001 in U.S. is claimed under 35 U.S.C. § 119.
- The certified copy of the priority application has been filed in application no. filed
- Amend the specification by inserting before the first line the following sentence: This is a continuation-in-part of application no. filed .

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted, by *Jacqueline Benn*
Laura A. Coruzzi Reg No 43,492
 Laura A. Coruzzi 30,742
 PENNIE & EDMONDS LLP (Reg. No.)

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

Express Mail No. EL 477 034 015 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Robert E. Klem

Application No.: To be Assigned

Art Unit: Not Yet Assigned

Filed: On Even Date Herewith

Examiner: Not Yet Assigned

For: METHODS AND COMPOSITIONS FOR
TREATING A CELL-PROLIFERATIVE
DISORDER USING CRE DECOY
OLIGOMERS, BCL-2 ANTISENSE
OLIGOMERS, AND HYBRID OLIGOMERS
THEREOF

Atty Docket No.: 10412-022

TRANSMITTAL OF SEQUENCE LISTING

Assistant Commissioner for Patents
Washington, DC 20231

SIR:

In connection with the above-identified application, and in accordance with 37 C.F.R. § 1.821, Applicant submits herewith a Sequence Listing in paper and computer-readable format pursuant to 37 C.F.R. § 1.821(c) and (e).

I hereby state that the content of the paper and computer-readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same. I hereby state that the submission herein under 37 C.F.R. § 1.821(g) does not include new matter.

Respectfully submitted,

By: Jacqueline Benn
Laura A. Coruzzi Reg. No. 43,492
Laura A. Coruzzi (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures